Dryneedling versus magnesium to release trigger points in myofascial pain syndrome: a randomized controlled study. - Trial PACTR202309751113430

Timeline & Enrollment

Summary

Myofascial pain syndrome (MPS) is one of the most common clinical musculoskeletal disorders, characterized by the existence of one or more myofascial trigger points (MTrPs) .The conventional definition of myofascial pain syndrome (MPS) is characterized by regional pain originating from hyperirritable spots located within taut bands of skeletal muscle (MTrPs) .Clinically, about 85% of patients who attend pain clinics have MTrPs.The highest prevalence is in trapezius muscles (93.75%), then in the levator scapulae (82.14%), and finally in the multifidi (77.68%) .The mechanism of pain in myofascial syndrome is complex. The pains are said to be referred, often accompanied by functional disorders.Also this syndrome remains unknown for the first line doctors, and will be considered as neck pain of degenerative origin or a painful shoulder.Lack of good treatment for a long period may result in headaches, dizziness or vertigo, neck and shoulder pain, sleep disorders, autonomic dysfunction, sensory abnormality, and limited neck and shoulder range of motion (ROM).Many treatment have been tried without evidence of efficacy: NSAID, anticonvulsivant…Injections into MTrPs are a common and effective treatment: Magnesium, TB, xylocaineSome authors Presume that this effect is due to mechanical disruption by the needle and termination of the dysfunctional activity of involved motor endplates. Yet, they use dryneedle to release trigger point. Our research question is: does dryneedle without active substance sufficient to release trigger point compared to a local injection of magnesium? We will compare the efficacy of a dryneedle versus magnesium in reducing pain in MPS

ICD-10 Classifications